Company Profile
Wuhan Emison Life Technology Co., Ltd. (Chinese: 武汉艾米森生命科技股份有限公司) is a China-based manufacturer of methylation-based cancer early detection reagents and systems, headquartered in Wuhan, Hubei. Founded in January 2015 by Dr. Zhang Lianglu, the privately held company is recognized as a national-level specialized and innovative "Little Giant" enterprise. Emison employs a 40-person R＆D team (as of end-2025) and holds five NMPA Class III medical device registrations, the most among early cancer detection companies in China. The company filed for an Hong Kong IPO on the Main Board in April 2026 (joint sponsors: CCB International and BOC International).
Core Products ＆ Technologies
Liver Cancer Early Screening
• Aixingan (艾馨甘): The world's first methylation-based qPCR liver cancer detection reagent; NMPA Class III approved January 2025; detects liver cancer via blood sample with 92.33% sensitivity, 93.35% specificity, and 84.43% sensitivity for Stage I patients; included in Beijing Class A (full reimbursement) and Shanxi provincial medical insurance catalogs
• Liver Cancer Recurrence Monitoring: New indication under development for post-treatment surveillance
Urothelial Cancer Early Screening
• Aiguangle (艾光乐): Non-invasive urothelial cancer detection using only 1 mL urine sample; NMPA Class III approved October 2025; 92.94% overall sensitivity and 92.83% specificity; addresses patient compliance limitations of traditional cystoscopy
Colorectal ＆ Esophageal Cancer Screening
• Aichangkang (艾长康): Colorectal cancer early screening reagent; NMPA Class III approved 2022; stool DNA methylation detection
• Aichangjian (艾长健): Colorectal cancer early screening reagent; NMPA Class III approved 2024
• Aisining (艾思宁): Esophageal cancer early screening reagent; NMPA Class III approved January 2025
Pipeline Candidates
• Aiweiyuan (艾卫元): Gastric cancer early detection candidate
• Aifeichang (艾斐畅): Lung cancer early detection candidate
• Aigongle (艾宫乐): Endometrial cancer early detection candidate
• Ailuyuan (艾露元): Multi-cancer combined screening candidate
Technology Platforms
• iTBFinder: AI-integrated intelligent tumor biomarker discovery platform built on over 210,000 multi-omics data entries, efficiently screening cancer-specific methylation biomarkers
• SEM-PCR (Sensitivity-Enhanced Methylation PCR): Proprietary technology increasing detection signal intensity by over tenfold, enabling stable detection at concentrations as low as 1 copy/µL
• AS-Cap (Amplification Selective Capture): Competitive capture probe design avoiding non-specific binding with bacterial and dietary DNA in stool samples, achieving high-specificity human DNA capture with sample volume reduced to 2 mL
Market Position ＆ Certifications
Emison holds a leading position in China's methylation-based cancer early screening market, competing with New Horizon Health, Burning Rock Biotech, Genetron Health, and BGI Genomics. Key strengths include:
• 10+ years of methylation detection technology heritage
• Regulatory leadership: Five NMPA Class III registrations covering colorectal, liver, esophageal, and urothelial cancers; all commercialized products hold EU CE-IVD certification
• Cost advantage: qPCR-based platform utilizing existing hospital equipment without new capital expenditure; per-test pricing significantly lower than NGS alternatives (average selling price around RMB 100 per test)
• Clinical validation: Products demonstrate high sensitivity for Stage I tumors, addressing the critical need for early-stage detection
• Intellectual property: 81 Chinese registered patents (including 59 invention patents) and 1 US registered patent
• Commercialization network: Coverage across 90 Chinese cities through direct sales to tertiary hospitals and premium health check centers, plus distributor networks for primary care penetration
Corporate Timeline
2015 — Founded in Wuhan by Dr. Zhang Lianglu, focusing on methylation-based cancer early detection
2022 — Aichangkang received NMPA Class III approval
2024 — Aichangjian received NMPA Class III approval; annual revenue reached RMB 7.238 million
2025 — Aixingan and Aisining received NMPA Class III approval in January; Aiguangle received NMPA Class III approval in October; first filed for Hong Kong IPO in September; annual revenue reached RMB 15.419 million with gross margin of 78.1%
2026 — Refiled Hong Kong IPO application on April 7; net assets turned positive to RMB 26.945 million as of December 31, 2025
Target Markets ＆ Applications
• Liver Cancer Screening: High-risk population surveillance and early diagnosis via blood-based methylation markers
• Urothelial Cancer Screening: Non-invasive urine-based detection for bladder cancer and upper tract urothelial carcinoma
• Colorectal Cancer Screening: Stool DNA methylation testing for adenoma and colorectal cancer early detection
• Esophageal Cancer Screening: Endoscopic companion diagnostics and population-based screening programs
• Multi-Cancer Risk Assessment: AI-integrated methylation platforms for pan-cancer early detection research and development
• Clinical Laboratories ＆ Hospitals: Reagent kits compatible with standard qPCR instruments in hospital labs and independent testing centers
Contact Information
Global Headquarters
Address: Room 04, 1F, Building B10, Phase I, Wuhan High-Tech Medical Device Park, No. 818 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei 430000, China
Email: hr@whams.com
Website: www.whams.com
